why Organon & Co. [OGN] is a Good Choice for Investors After New Price Target of $39.29


Organon & Co. [NYSE: OGN] price surged by 5.06 percent to reach at $1.68.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


A sum of 3414421 shares traded at recent session while its average daily volume was at 2.17M shares. Organon & Co. shares reached a high of $35.21 and dropped to a low of $33.15 until finishing in the latest session at $34.87.

The one-year OGN stock forecast points to a potential upside of 11.25. The average equity rating for OGN stock is currently 2.30, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Organon & Co. [OGN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OGN shares is $39.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OGN stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Goldman have made an estimate for Organon & Co. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 27, 2022. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on April 06, 2022, representing the official price target for Organon & Co. stock. Previously, the target price had yet another raise to $35, while Piper Sandler analysts kept a Neutral rating on OGN stock.

The Average True Range (ATR) for Organon & Co. is set at 1.05, with the Price to Sales ratio for OGN stock in the period of the last 12 months amounting to 1.43. Price to Free Cash Flow for OGN in the course of the last twelve months was 4.11 with Quick ratio for the last quarter at 1.10.

OGN Stock Performance Analysis:

Organon & Co. [OGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.67. With this latest performance, OGN shares dropped by -1.50% in over the last four-week period, additionally sinking by -5.30% over the last 6 months .

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OGN stock in for the last two-week period is set at 57.05, with the RSI for the last a single of trading hit 63.84, and the three-weeks RSI is set at 54.01 for Organon & Co. [OGN]. The present Moving Average for the last 50 days of trading for this stock 34.93, while it was recorded at 32.98 for the last single week of trading, and 33.24 for the last 200 days.

Insight into Organon & Co. Fundamentals:

Organon & Co.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Organon & Co. go to -5.00%.

Organon & Co. [OGN] Insider Position Details

There are presently around $5,858 million, or 72.20% of OGN stock, in the hands of institutional investors. The top three institutional holders of OGN stocks are: VANGUARD GROUP INC with ownership of 28,774,673, which is approximately -0.118% of the company’s market cap and around 0.02% of the total institutional ownership; BLACKROCK INC., holding 16,900,502 shares of the stock with an approximate value of $560.93 million in OGN stocks shares; and STATE STREET CORP, currently with $310.61 million in OGN stock with ownership of nearly 3.78% of the company’s market capitalization.

Positions in Organon & Co. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 309 institutional holders increased their position in Organon & Co. [NYSE:OGN] by around 19,070,661 shares. Additionally, 571 investors decreased positions by around 19,408,518 shares, while 142 investors held positions by with 138,029,247 shares. The mentioned changes placed institutional holdings at 176,508,426 shares, according to the latest SEC report filing. OGN stock had 107 new institutional investments in for a total of 2,682,248 shares, while 179 institutional investors sold positions of 7,510,937 shares during the same period.